Arcus Biosciences Inc
$ 28.62
1.02%
07 Aug - close price
- Market Cap 3,599,628,000 USD
- Current Price $ 28.62
- High / Low $ 29.11 / 28.01
- Stock P/E N/A
- Book Value 5.04
- EPS -3.98
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.91 %
- 52 Week High 31.73
- 52 Week Low 8.88
About
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Analyst Target Price
$38.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-05 | 2026-02-25 | 2025-10-28 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-21 | 2023-11-07 |
| Reported EPS | -0.72 | -1.02 | -0.89 | -1.27 | 0 | -1.14 | -1.03 | -1 | -1.02 | 0.19 | -1.08 | -0.94 |
| Estimated EPS | -0.98 | -0.83 | -1.1 | -1.29 | -1.17 | -1.01 | -1.2031 | -1.07 | -1.39 | -1.03 | -1 | -1.1 |
| Surprise | 0.26 | -0.19 | 0.21 | 0.02 | 1.17 | -0.13 | 0.1731 | 0.07 | 0.37 | 1.22 | -0.08 | 0.16 |
| Surprise Percentage | 26.5306% | -22.8916% | 19.0909% | 1.5504% | 100% | -12.8713% | 14.3878% | 6.5421% | 26.6187% | 118.4466% | -8% | 14.5455% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RCUS
2026-08-07 20:42:55
Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration Agreement providing Gilead with exclusive licensing options on Arcus programs. While a prior option allowing Gilead to increase its stake to 35% expired in July 2025, Gilead states it currently has no specific plans for major corporate actions, but may review its investment over time.
2026-08-06 19:41:01
Arcus Biosciences, Inc. (RCUS) reported Q2 revenue of $41.0 million. Wedbush adjusted its price target on Arcus Biosciences to $43 from $41, maintaining an Outperform rating. The company is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, with several investigational products in clinical development.
2026-08-06 19:41:01
Wells Fargo & Company has raised its price target for Arcus Biosciences (NYSE:RCUS) from $23.00 to $26.00, while maintaining an "equal weight" rating. This new target implies a potential downside of 5.75% from the stock's previous close. Despite this, the company has a "Moderate Buy" consensus rating from analysts with an average price target of $36.90. Arcus Biosciences recently reported better-than-expected quarterly earnings and revenue, though revenue was down year-over-year.
2026-08-06 17:40:11
The average 12-month price target for Arcus Biosciences, Inc. stock has increased from $37.17 to $38.25, based on estimates from 12 analysts. This new target suggests a potential upside of approximately 38% from the August 5 closing price. The consensus rating among 13 analysts remains a "Buy," with 10 Buy recommendations and 3 Holds.
2026-08-05 20:13:14
Arcus Biosciences reported its second-quarter 2026 financial results, with revenues of $41 million and a net loss of $91 million. The company is strategically advancing its HIF-2α inhibitor, casdatifan, for clear cell renal cell carcinoma (ccRCC) through three new clinical trial collaborations and anticipates multiple data readouts in the second half of 2026. Arcus expects its cash reserves of $775 million to fund operations until at least the second half of 2028.
2026-08-05 20:13:14
Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option rights over Arcus's early-stage pipeline have ended, although Gilead retains time-limited options on specific programs and a substantial equity stake. Arcus is advancing its HIF-2α inhibitor casdatifan through new collaborations while discontinuing two Phase 3 TIGIT trials, managing expenses, and expects its $775 million in cash and investments to fund operations until at least the second half of 2028.
